AIM ImmunoTech, Inc.
(NYSE Amex Equities : AIM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 3.49%219.440.0%$2040.26m
BIIBBiogen, Inc. -4.27%356.021.7%$1233.77m
SNSSSunesis Pharmaceuticals, Inc. 6.47%11.850.7%$828.36m
NVAXNovavax, Inc. 0.91%193.9879.8%$827.79m
AMGNAmgen, Inc. 1.12%241.381.3%$644.53m
BNTXBioNTech SE 0.75%231.230.0%$577.26m
VRTXVertex Pharmaceuticals, Inc. 2.63%192.461.9%$541.53m
GILDGilead Sciences, Inc. 1.93%67.941.0%$485.03m
REGNRegeneron Pharmaceuticals, Inc. 1.94%540.062.7%$393.60m
OCGNOcugen, Inc. 1.19%7.650.0%$349.89m
ILMNIllumina, Inc. 0.76%472.673.5%$349.55m
ALXNAlexion Pharmaceuticals, Inc. 1.20%181.992.0%$335.71m
EXASEXACT Sciences Corp. 0.30%131.3718.1%$176.59m
TXG10X Genomics, Inc. -1.67%198.040.0%$175.73m
BNGOBionano Genomics, Inc. -0.15%7.240.0%$155.90m

Company Profile

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.